Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.42 USD
+0.06 (1.79%)
Updated Jun 3, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Arbutus Biopharma Corporation [ABUS]
Reports for Purchase
Showing records 61 - 80 ( 191 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials; Multiple AB-729 Cohort Readouts in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q4 Financials; AB-729 SAD Data Coming This Month
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Light at the End of the Tunnel Not So Bright
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D